Dupuytren's contracture is a disease associated with bending of fingers towards the palm. Collagenase clostridium histolyticum is an enzyme which helps in treating Dupuytren's contracture by dismantling the collagen. This enzyme helps to break down the chord of thickened tissue and allows straightening of fingers. The major symptoms include thickening of palm with or without pain, loss of motion of fingers, and loss of grip. This disease mostly affects the ring finger; it starts with the palm and moves towards fingers. Collagenase clostridium histolyticum injections are also used to cure Peyronie's disease which is a connective tissue disorder inside the penis, causing it to curve. The report analyzes the market penetration rate of collagenase clostridium histolyticum in both the diseases- Dupuytren's contracture and Peyronie's disease.
The use of collagenase clostridium histolyticum is associated with various side effects. For the person with Dupuytren's contracture, the side effects are redness, swelling, and tenderness, bruising, or bleeding around the injected area, itching of the treated hand, pain in the treated hand, painful and swollen glands in the elbow or underarm area. With a person suffering from Peyronie's disease, the side effects include blisters at the injection site, lump at the injection site, changes in color of the skin of penis, itching of the penis or scrotum, painful erection, erection problems, and painful sexual activity. Sometimes the side effects could be severe and need immediate treatment. The report covers the types of medications used in various regions. For example, XIAFLEX is a prescribed and approved medicine by the Food and Drug Administration of the United States used to treat adults with Dupuytrens contracture and Peyronie's disease; whereas XIAPEX is authorized in the European Union (EU) for the same diseases. These medications were prepared by Biospecifics Technologies which are manufactured and marketed by Auxilium Pharmaceuticals in the U.S. whereas, Sobi & Pfizer manufactures and market the XIAPEX drug in European region.
The report identifies and analyzes the key industry factors affecting the revenue generation in the collagenase clostridium histolyticum market. It also includes the major market dynamic factors such as drivers, restraints, challenges and opportunities and their impact on the industry in next 5 years. The report tracks the entire value chain of the collagenase clostridium histolyticum market along with the suppliers and distributor analysis. Moreover, the industry attractiveness section in the offers the significance of the competitive rivalry in the market affected by the forces such as power of supplier, power of buyer, threat of new entrant and threat of substitution. The report provides precise and comprehensive insights on the market trends, industry trends, and macro & micro factors impacting the market growth.
The market of collagenase clostridium histolyticum in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America. North America accounts for highest share due to the high adaptive rate of the medications and disease awareness. Moreover, Europe also accounts for second largest share in the global market due to increasing number of patients suffering from Dupuytrens contracture and Peyronie's disease.Moreover, the countries generating high revenue in these regions have also been analyzed along with exhaustive coverage of developments and innovation in these countries.
The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers & acquisitions, partnerships, collaborations, and contracts adopted by the major players are also identifies and analyzed in the report.
Sample Companies Profiled in this Report are:
- Auxilium Pharmaceuticals, Inc
- Biospecifics Technologies Corp
- Actelion Pharmaceuticals Canada Inc
- Advanced Biofactures Corporation
- Healthpoint Ltd